Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7f68db0eca89cfaf3fe3936e9035edd |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16334 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-826 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16 |
filingDate |
1998-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c1afe574c00b5939380fac69f074a02 |
publicationDate |
2003-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
MX-PA00006263-A |
titleOfInvention |
ANTI-RETROVIRAL IMMUNOGEN, ITS PREPARATION AND ITS USE. |
abstract |
The present invention relates to a regulatory retroviral protein or fragment of such protein or interferon alpha or carboxymethylated interferon alpha fragments. The chemical modification described produces new proteins and fragments of biologically inactive proteins but which induce an immunogenic response. The proteins described can be used for the prevention and treatment of SI |
priorityDate |
1997-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |